New Job Opportunity

Sanofi to Invest €400 Million in Expanding Hyderabad GCC, Aiming for 2600 Employees

Sanofi Healthcare India Pvt. Ltd. announces the expansion of its Global Capacity Centre (GCC) in Hyderabad, with plans to invest €400 million over the next six years, with €100 million by 2025. Over the next two years, this GCC (hub) will expand to host up to ~2600 employees, making it the largest of Sanofi’s four global hubs. Sanofi’s 4 Global Capacity Centres are strategic Hubs across the Globe that give the company a competitive edge in delivering best-in-class enterprise solutions. These hubs are key ‘nervecenters’ that enable centralization and modernization and allow for scaling-up opportunities across Sanofi’s value chain, offering a wide array of services ranging from commercial, manufacturing & supply to R&D and digital. Madeleine Roach, Executive Vice President, Business Operations, Sanofi “I thank Hon’ble Minister Sri Duddilla Sridhar Babu for welcoming Sanofi’s largest GCC and inaugurating our new workplace. Hyderabad is emerging as a preferred shared services destination with a large pool of talent. We’re excited to invest and build this hub here to become a great global community striving for excellence, with digitalization at the heart of our transformation. This hub will be a catalyst enabling Sanofi to accelerate efficiency and reinvent how we work, as we chase the miracles of science to improve people’s lives.” Emmanuel Frenehard ,Executive Vice President, Chief Digital Officer, Sanofi“Our ambition is to be the first biopharma company powered by Artificial Intelligence (AI) at scale. From discovery to treatment, we are using AI ethically and safely to get to market faster with our drugs as there's plenty of unmet needs. We intend to onboard talent at the Hyderabad hub to embrace the power of AI across our value chain to harness the pace of scientific discovery, improve our productivity and place better decision intelligence in the hands of our people.

Nipro Expands in the U.S. with First North American Manufacturing Facility, Creating 232 Jobs

Nipro Medical Corporation, a leader in the global healthcare and medical device industry, proudly announces its significant expansion in the United States with the establishment of its first North American manufacturing facility in Greenville, North Carolina. This strategic development is set to generate 232 new jobs. Governor Roy Cooper expressed his enthusiasm about Nipro’s decision to expand to North Carolina, highlighting the state's reputation as a center for advanced manufacturing. “We are delighted to welcome Nipro to North Carolina," Governor Cooper stated. "This initiative not only reinforces our status as a prime location for advanced manufacturing but also demonstrates our state's capability in providing a skilled workforce and a superior quality of life.” Akira Shimizu, CEO of Nipro Medical Corporation, reflected on the significant impact of this expansion. “This new facility marks a major milestone in Nipro's commitment to the U.S. market, allowing us to deliver high-quality medical devices that enhance patient outcomes and quality of life across the country,” said Shimizu. N.C. Commerce Secretary Machelle Baker Sanders noted, “North Carolina’s rich environment for STEM talent and our robust manufacturing workforce make it an ideal location for global healthcare leaders like Nipro. Our commitment to fostering growth ensures that North Carolina remains at the forefront of medical innovation and manufacturing.” Krizay Elenitoba-Johnson, Vice President of Manufacturing Operations and Inaugural Site Leader for the Greenville Medical Device Plant, expressed anticipation for the collaborative opportunities ahead. “I look forward to working with our dedicated team and the supportive community here to achieve great successes,” Elenitoba-Johnson remarked.

Merck Begins Commercial Production of First GMP-Compliant Cell Culture Media Line in China

Merck, a leading science and technology company, announced the start of commercial production of its first GMP (Good Manufacturing Practices) compliant manufacturing line for cell culture media (CCM) in China. The approximate € 6.6 million investment at its Life Science Center in Nantong – a major industrial hub in the Yangtze River Delta region – aims to address the growing local demand for quality custom CCM used in biopharmaceuticals, vaccines, and novel therapeutics. Commercialization of the local production line enables Chinese customers to access Merck’s well-established custom CCM products and services in a reliable and efficient manner. Leveraging extensive in-house formulation knowledge, Merck designs robust custom CCM for customers’ specific processes and creates innovative solutions that enhance consistency and efficiency of their processes. “This investment further expands Merck's footprint and capabilities in China, showcasing our commitment to the development of the local biopharma industry,” said Roy Wu, Managing Director of the Life Science business sector, Merck China. “The new cell culture media manufacturing line is a positive proof of our commitment to improve patient care by leveraging our innovative spirit and global network of expertise.” Applying media components from qualified sources only, the Nantong GMP facility allows for a smooth transition from pilot to commercial-scale cell culture production with comprehensive regulatory documentation. Along with tailor-made dry powder CCM products, customized technical and operational assistance will also be provided to support local biopharma manufacturers’ processes and shorten time to market. Product lead time is expected to be reduced as a result of local manufacturing. “The Nantong Economic and Technological Development Area (NETDA) is focused on accelerating high-quality development of its biopharma industry,” said Cao Haifeng, Deputy Secretary of NETDA Party Working Committee and Director of NETDA Administrative Committee. “The project of Merck's Life Science Center in Nantong will provide important contributions to the biopharma eco-system of the region.”

CordenPharma expands its peptide platform in US and Europe

CordenPharma has announced its largest strategic investment to date with a committed spend of ~€900m over the next 3 years to grow its Peptide technology platform. These transformational plans consist of two major expansion initiatives occurring in parallel in the US and Europe, including both existing facilities and new constructions designed and built according to the pharmaceutical industry’s most stringent quality and technical standards for short and long peptide manufacturing, including Biologics License Applications (BLA) requirements. The US expansion involves bringing additional Peptide capacity to the CordenPharma Colorado site with the planned construction of a new large-scale manufacturing facility, and an additional increase in manufacturing trains in the existing facility. This is the result of rapidly increasing demand in the Diabetes and Obesity Glucagon-like Peptide 1 (GLP-1) agonist medications market, and comes off the back of multiple, long-term, multiyear contracts totaling ~€3bn, with potential upsides. The European expansion centers on the construction of a new state-of-the-art greenfield facility, with the aim of creating additional Peptide capacity to serve customers from initial early clinical to late-stage commercial manufacturing. The new site will be located in the heart of Europe, fully-integrated within CordenPharma’s existing facility network. Dr. Michael Quirmbach, President & CEO of the CordenPharma Group comments: “These investments will profoundly strengthen our ability to provide valuable and much needed support to innovators for the benefit of patients. We are honored by the trust our customers have placed in us to deliver expert outsourcing for large multiyear contracts, and our team is proud to contribute decades of peptide manufacturing experience towards these transformative new medicines. In addition, the strong commitment and support of our shareholder Astorg demonstrates their strategic vision for CordenPharma to become the leading CDMO for complex modalities such as Peptides, by offering fully-integrated end-to-end services from APIs to Drug Products (for both Injectable and Oral Peptides).” Dr. Signe Michel, Managing Director at Astorg comments: “We are proud of what Michael and the CordenPharma team have achieved through their striving for operational excellence, customer service and ambitious growth. We are excited about the opportunities ahead and to further strengthen the company’s peptide offering across the full drug lifecycle and value chain.” Judith Charpentier, Co-Head Flagship Fund and Head of Healthcare at Astorg comments: “CordenPharma has a unique opportunity to reinforce its leadership position in peptides with unmatched capacity and performance in large scale manufacturing. With the company’s proven track record and our investor experience in pharmaceutical services, we feel confident that our latest commitment will help the company seize this opportunity.”

INCOG BioPharma Accelerates Expansion Plans, Creates 100 High-Paying Jobs

INCOG BioPharma Services, a contract development and manufacturing organization (CDMO) specializing in sterile injectable biopharmaceuticals, is excited to announce a new investment to expand its manufacturing capabilities. The expansion includes the construction of a second 100,000-square-foot building on its campus, set to break ground in August. This will increase the company's commercial-scale device assembly capacity in support of autoinjectors, pens, wearable injectors, and syringe accessorizing, while also adding new labeling and final packaging capabilities. The second building will further enable INCOG to offer comprehensive, end-to-end solutions from filling to device assembly and final packaging, streamlining the process and simplifying the supply chain solution for its global biopharma customers. "We are excited about this new investment and the opportunities it brings," said Cory Lewis, CEO and Founder of INCOG. "Our customers will have access to a suite of solutions from filling through final packaging. This supply chain integration is essential in accelerating a drug product to commercial launch, and even more important in today's constrained markets as the need for sterile injectable products is quickly growing to address challenging diseases and improve healthcare outcomes. The hard work and expertise of the team we have built at INCOG has allowed us to accelerate investments and address the immediate needs of the global biopharma industry." This expansion will create over 100 additional high-paying jobs, further establishing Fishers, and the state of Indiana, as a global leader in biopharmaceutical innovation and manufacturing. The Indiana Economic Development Corporation cited research showing that the state is the largest exporter of pharmaceutical products in the continental United States. At the end of 2023, Indiana's Life Science sector had over 3,000 companies, employing 67,000 people and contributing $95 billion to the state's economy. The IEDC and the City of Fishers played a pivotal role in supporting INCOG to obtain the necessary funding for the expansion. "We are proud to contribute to the social and economic growth of Fishers, by creating new jobs and fostering a vibrant life science community," added Lewis. "The city and IEDC have served as an extension of our team. It's exciting to bring current and prospective clients to our facility so they can experience the growing community where we do business." "We are incredibly proud to witness INCOG's growth and expansion into a second building," said Fishers Mayor Scott Fadness. "This expansion reinforces Fishers as a leading hub for life sciences and biopharma manufacturing. INCOG has played a significant role in building the industry cluster in Fishers, and we look forward to celebrating their future successes." This project comes on the heels of current work to commission and install a second high-speed syringe and cartridge filling line, along with supporting automated visual inspection equipment. The new filling line complements INCOG's existing multi-use filling line, bringing the site's filling capacity to 140 million units per year. The automated visual inspection and autoinjector assembly capabilities are available now, with the additional syringe filling capacity coming online in Q2 2025. These enhancements further enable INCOG to meet the growing demand for biopharmaceutical solutions that utilize pre-filled syringes and autoinjector delivery mechanisms.

Medicus Healthcare Solutions Releases White Paper Addressing the Radiologist Shortage in U.S. Healthcare

Medicus Healthcare Solutions, a leading locum tenens agency, announces the release of its 2024 white paper "Navigating the Radiologist Shortage." Healthcare in the United States is undergoing significant challenges, with a growing concern about the availability of physicians, particularly in specialized fields such as radiology. The shortage of radiologists is beginning to reach critical levels, exacerbated by the growing disparity between graduation and retirement rates. As a result, the staffing shortfall is a pressing concern that is sparking nationwide discussion. This white paper includes the latest insights into the radiology workforce, contributing factors impacting the radiologist shortage, and strategies for how healthcare employers can effectively navigate and address the radiologist shortage. Bob Dickey, CEO of Medicus Healthcare Solutions, shared, "Our white paper highlights the shortage and offers strategies to address rising demand. Medicus is committed to helping healthcare leaders manage immediate staffing needs and ensure long-term stability through our Medicus Transition Program, which streamlines clinical workforce stabilization amidst ongoing staffing challenges." Key Highlights Include: Current Workforce Demographics and Projections: The latest data on active radiologists and insights into the current and projected radiologist shortage. Radiology by the Numbers: Statistics on the number of residency positions, job outlook, and projected shortages in the radiology field. Tips for Overcoming the Shortage: Leverage innovative approaches to address burnout, retention issues, and workforce planning, informed by the most recent industry trends and best practices. Hospitals, physician groups, and healthcare facilities across the country, along with radiologists, are increasingly impacted by the radiology shortage. The widening gap between the demand for radiology services and the available number of radiologists underscores the urgent need for proactive measures

Veranova Announces New Investment to Expand ADC and Highly Potent API Capabilities

Veranova, a global leader in the development and manufacturing of specialist and complex APIs for the pharmaceutical and biotech sectors, announced initiation of a significant expansion of its antibody-drug conjugate (ADC) and highly potent compound development and manufacturing capabilities at its Devens, MA facility. The estimated $30 million investment will build upon the site’s existing development and manufacturing capabilities and will address the growing demand for strong US-based capacity for ADCs and other potent small molecules. The expansion will include a new high potent process development laboratory and two new cGMP suites designed to handle potent compounds with occupational exposure limits (OEL) of less than 0.01 µg/m³. These facilities, equipped to manage high-potency compounds, ADC linker-payloads, and other complex molecules, will feature dedicated air handling systems, airlocks for clean-in-place operations, isolator technology, and a comprehensive range of processing capabilities, including synthesis reactors, chromatography, thin film evaporators, and lyophilization. “At Veranova, we recognize the growing demand for development and manufacturing of ADCs and other highly potent compounds,” said Mike Riley, CEO of Veranova. “This investment signals our commitment to providing state of the art capacity and capabilities to enable these next generation therapies to reach patients, and is a key milestone as we advance our broader growth strategy for Veranova.” Strategically located near the Boston pharmaceutical and biotech hub, Veranova’s Devens site is an FDA-approved facility that boasts over 10 years of experience in the development, scale-up, and clinical and commercial production of ADC linker-payloads and other highly potent APIs. Uniquely positioned to perform development, clinical manufacturing, and commercial manufacturing all under one roof, the Devens facility eliminates the need for tech transfers and leverages Veranova’s leading capabilities in both crystallization development and chromatography.

Cambrex to Expand Stability Storage Business with New Facility

Cambrex announced the expansion of its stability storage business, Q1 Scientific, which offers environmentally-controlled stability storage services to the pharmaceutical, medical device, and life sciences industries. Q1 Scientific will open a new state-of-the-art facility in Durham, North Carolina before the end of 2024, featuring advanced storage capabilities and co-located next to the existing Cambrex analytical facility. The facility's Research Triangle Park (RTP) location in North Carolina will provide same day and next day delivery across the US. Tom Loewald, CEO at Cambrex, stated, "We are thrilled to expand Q1 Scientific's reach into Durham, North Carolina, enhancing our ability to serve pharmaceutical companies across North America. This investment not only broadens our footprint but also leverages Q1 Scientific's extensive expertise in the stability storage business." Q1 Scientific's expansion into Durham complements its existing facilities in Waterford, Ireland, and Liège, Belgium, giving it a global footprint with three locations covering both sides of the Atlantic Ocean. Stephen Delaney, Managing Director of Q1 Scientific, added, "Operating three sites globally will be a significant benefit to our customers, who can now expect faster turnaround times for the return of samples and greater temperature-controlled transport options across the US and Europe." Cambrex continues to expand its capabilities and capacity across its North American and European network to meet the growing demand for outsourced drug development and manufacturing services.

LOTTE BIOLOGICS Holds Groundbreaking for Songdo Bio Campus

LOTTE BIOLOGICS, under the leadership of CEO Richard W. Lee, held a groundbreaking ceremony for its inaugural plant at the Songdo Bio Campus in Incheon International City. The auspicious occasion drew a distinguished assembly of approximately 300 guests, including LOTTE Group Chairman Dong-Bin Shin, Incheon Mayor Jeong-Bok Yoo, National Assembly Member Il-Young Jung representing Incheon Yeonsu District, First Vice Minister of Trade, Industry and Energy Kyung-Sung Kang, Second Vice Minister of Health and Welfare Min-Soo Park, and Incheon Free Economic Zone Commissioner Won-Seok Yoon. Prime Minister Duck-Soo Han also conveyed his congratulations via video message. LOTTE Group is currently expanding its businesses centered around four themes: 'Bio & Wellness,' 'Mobility,' 'Sustainability,' and 'Novel Life Platforms.' The Songdo Bio Campus, a cornerstone of the Bio & Wellness sector, represents an investment of approximately 4.6 trillion won. This state-of-the-art facility, spanning an impressive 202,285.2 square meters, is set to house three cutting-edge production plants alongside essential auxiliary buildings. LOTTE Engineering & Construction will spearhead the design, procurement, and construction of the first plant, showcasing the group's integrated approach to this transformative project. Each plant is planned to have a production capacity of 120,000 liters, totaling 360,000 liters across the campus. The scale of this endeavor is further emphasized by its projected economic impact of 7.6 trillion won and the creation of 37,000 related jobs, illustrating LOTTE BIOLOGICS' commitment to both industrial advancement and socioeconomic growth. Addressing the gathering, LOTTE Chairman Dong-Bin Shin articulated a vision that extends beyond corporate growth: "The journey of LOTTE BIOLOGICS, commencing here in Songdo, is poised not only to become a future growth engine for LOTTE Group but also to reshape Korea's biotech industry landscape. Our unwavering commitment is to contribute significantly to the successful establishment of Songdo's bio cluster, thereby propelling Korea to the forefront of the global biotech arena." This sentiment was echoed and amplified by Prime Minister Duck-Soo Han in his video address. Recognizing the intensifying global competition in the biotech market, he stated, "LOTTE Group's bold investment is expected to substantially enhance the competitiveness of Korea's biopharmaceutical industry." The Prime Minister went on to outline the government's supportive stance, pledging to "actively facilitate 36.3 trillion won in private sector investment planned by 2040, centered around the recently designated National Advanced Strategic Industry Specialized Complex for Biotechnology." LOTTE BIOLOGICS CEO Richard W. Lee offered his own perspective in his address: "I would like to express my heartfelt gratitude to the government agencies and institutional representatives who have provided invaluable support in bringing us to this momentous occasion." He then articulated the company's ambitious trajectory, stating, "LOTTE BIOLOGICS is committed to evolving into a global TOP 10 bio-CDMO by 2030. Through this growth, we aspire to serve as a driving force to propel Korea to the forefront of the global bioeconomy, establishing our nation as a leading force in this critical sector."

OrganOx Opens State-of-the-Art Research, Development, and Production Headquarters in Oxford, UK

OrganOx Ltd, a world-leading medical technology company developing innovative solutions for organ preservation prior to transplantation, and for the treatment of acute organ failure, is proud to announce the official opening of a new 18,000 square-foot global research, development, and production headquarters in Oxford, UK. Originally spun out from the University of Oxford in 2008, OrganOx developed the world’s first normothermic liver perfusion device, the metra®. The metra® launched across Europe in 2018 and in the U.S. in 2022 and has gained rapid market adoption since, enabling more organ transplants, eradicating night-time operating, and improving patient outcomes. “Our new facility opening is a major milestone, providing OrganOx stakeholders access to world-class facilities and technologies as we work together in ways that were simply not possible previously,” said Craig Marshall, CEO. “We are proud to be a growing member of the Oxford business and scientific community, and I am greatly looking forward to broader collaborations with commercial and clinical partners.” Prof. Peter Friend, FMedSci, Chief Medical Officer, and Co-Founder of OrganOx, commented, “We are all excited about what the future holds for OrganOx as we continue to push the scientific and clinical boundaries with technology-based solutions designed to improve the lives of patients experiencing acute or chronic organ failure. This remarkable new facility will support us in that mission for many years to come.” “Peter and I, surgeon and engineer, could scarcely imagine a day like this when we first began collaborating in an Oxford University laboratory more than 20 years ago,” said Prof. Constantin Coussios, OBE FREng FMedSci, Chief Technology Officer, and Co-Founder of OrganOx. “It is truly remarkable and a testament to the dedication and efforts of a great many researchers, engineers, transplant surgeons, staff, customers, patients, and business partners, whom we celebrate on this occasion.”